- Conditions
- Pancreatic Cancer, Liver Cancer, Lung Cancer, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC), Hepatobiliary Cancers, Hepatobiliary Cancers Liver, Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma), Hepatobiliary Cancers Gallbladder, Hepatobiliary Cancers Bile Duct
- Interventions
- MR Imaging
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 3,989
matching trials from the live ClinicalTrials.gov search.
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- U3-1287, Erlotinib, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 14
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Anaheim, California + 11 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- DRP-104
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 45
- States / cities
- Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more
- Conditions
- Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- tipifarnib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lung Cancer
- Interventions
- ZD6474, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- Celecoxib, Docetaxel
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine, Intensity-Modulated Radiation Therapy (IMRT), Pemetrexed Disodium, Stereotactic Body Radiation Therapy (SBRT), Erlotinib Hydrochloride, Pembrolizumab
- Radiation · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 296
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 228 more
- Conditions
- Lung Cancer
- Interventions
- computed tomography, fludeoxyglucose F 18, hypofractionated radiation therapy, stereotactic radiosurgery
- Procedure · Radiation
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- quaratusugene ozeplasmid, atezolizumab
- Biological
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 17
- States / cities
- Lone Tree, Colorado • St Louis, Missouri • Canton, Ohio + 9 more
- Conditions
- Solid Tumor, Adult
- Interventions
- DF9001, KEYTRUDA® (pembrolizumab)
- Drug
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Tumors
- Interventions
- INC280
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 5
- States / cities
- Fayetteville, Arkansas • Chicago, Illinois • Detroit, Michigan + 2 more
- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, pemetrexed disodium
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
- Conditions
- Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
- Interventions
- AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Weston, Florida • Chicago, Illinois + 2 more
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer
- Interventions
- Capmatinib, Trametinib
- Drug
- Lead sponsor
- Collin Blakely
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
- Interventions
- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13, Modified Medical Research Council, EQ-5D, Center for Epidemiological Studies Depression Scale, Medical Outcomes Study Social Support Survey
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- hSTC810 400 mg + Paclitaxel, hSTC810 800 mg + Paclitaxel
- Drug
- Lead sponsor
- STCube, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Pemetrexed, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 18
- States / cities
- Chicago, Illinois • Evanston, Illinois • Galesburg, Illinois + 13 more
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Surgical Procedure, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Docetaxel, Vinorelbine, Nivolumab, Pembrolizumab, Atezolizumab, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 415
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Lung Cancer
- Interventions
- Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo
- Biological · Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 52
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 40 more
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
- Interventions
- Biospecimen Collection
- Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Pemetrexed, Gemcitabine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota